If you have spent years collecting diagnoses that do not quite fit — anxiety, IBS, “stress,” “it’s hormonal,” chronic urticaria, fibromyalgia — and you can list a dozen seemingly unrelated symptoms that flare on the same days, you are not imagining it. You may be describing mast cell activation syndrome, or MCAS.
MCAS is one of the most under-recognized contributors to complex chronic illness in women, and it overlaps heavily with conditions that already get missed: POTS, Ehlers-Danlos syndrome (EDS), long COVID, and chronic Lyme. In Oklahoma City and Tulsa, very few clinics screen for it at all.
This guide is meant to help you understand what MCAS actually is, the consensus criteria clinicians use to identify it, and what care can look like when a physician takes the whole picture seriously. Nothing here is medical advice, and no treatment described is a cure for MCAS or any related condition. The goal is simply to give you a clearer map of the territory so you can have a better conversation with a clinician.
What Is MCAS?
Mast cells are immune cells that live in your skin, gut, airways, blood vessels, and the lining around your nerves. When they are working normally, they release histamine, tryptase, and other chemical messengers in measured amounts as part of your immune response.
In MCAS, mast cells become inappropriately reactive. They release their mediators in response to triggers that should not provoke a reaction — heat, stress, certain foods, fragrances, hormonal shifts, infections, even standing up. The result is a constellation of symptoms across multiple body systems that can look like a dozen different conditions at once.
The Mast Cell Disease Society, the leading patient advocacy and education organization in this space, distinguishes MCAS from related disorders like systemic mastocytosis (where mast cells are abnormal in number) and hereditary alpha-tryptasemia. For most patients reading this article, MCAS is the relevant label — meaning the cells are normal in number but behave abnormally.
Why It Gets Missed
Three reasons MCAS goes undiagnosed for years:
- The symptom list is enormous. Patients are routed to a different specialist for each symptom, and no one assembles the full picture.
- Standard allergy panels look normal. IgE-mediated allergy testing does not detect mast cell over-activation, so patients are told “you don’t have allergies” and sent home.
- Lab evidence is fleeting. Mediators like tryptase and N-methylhistamine are easiest to capture during a flare, not weeks later in a routine draw.
MCAS Symptoms — Especially in Women 30+
MCAS does not look like one thing. It looks like a pattern across multiple organ systems that appear and disappear together. The most common symptoms our patients describe:
Skin:
- Flushing (face, chest, neck)
- Hives or “stress rashes” that come and go
- Itching without a visible rash
- Dermatographia (skin that draws lines when scratched)
Gastrointestinal:
- Bloating, abdominal pain, reflux that started in adulthood
- New food intolerances that keep expanding
- Diarrhea and constipation alternating
- Nausea without an obvious cause
Cardiovascular and autonomic:
- Racing heart on standing (POTS overlap)
- Blood pressure swings
- Near-fainting episodes
- Chest tightness without cardiac findings
Neurological:
- Brain fog, especially after meals or hormonal shifts
- Headaches and migraines
- Anxiety that worsens with reactions, not the other way around
- Sleep disturbance, especially around the menstrual cycle
Respiratory:
- Shortness of breath, throat tightness
- Persistent post-nasal drip with negative allergy testing
Systemic:
- Fatigue that does not improve with rest
- Temperature dysregulation
- Worsening of all symptoms around perimenopause
The pattern is what matters. One symptom in isolation is not MCAS. A reproducible cluster across two or more systems, with identifiable triggers and a response to mast-cell-targeted strategies, is the picture clinicians look for.
Diagnostic Criteria — What Doctors Are Actually Looking For
The international consensus criteria most often cited (Valent et al., and the updated criteria published by the Mast Cell Disease Society) require three elements:
- A pattern of episodic symptoms consistent with mast cell mediator release, affecting two or more organ systems.
- Objective evidence of elevated mast cell mediators — most commonly serum tryptase drawn during or just after a flare (with comparison to baseline), or 24-hour urine for N-methylhistamine, prostaglandin D2, or leukotriene E4.
- A response to mast-cell-targeted therapy — typically H1 and H2 antihistamines and mast cell stabilizers.
In practice, getting the lab evidence is the hardest step, because mediators fall back to baseline quickly. Specialty labs and timed draws (within 1–4 hours of a flare) are often required. A clinician familiar with MCAS will plan this collection intentionally rather than relying on routine draws.
For a deeper dive into the criteria themselves, the Mast Cell Disease Society’s overview of MCAS is the most authoritative patient-facing resource.
The Conditions That Travel With MCAS
If you are exploring MCAS, you should also know about the conditions that overlap with it. Recognizing the overlap is often what finally unlocks the diagnosis.
POTS (Postural Orthostatic Tachycardia Syndrome): Many MCAS patients have POTS. Standing triggers mast cell activation, which in turn worsens autonomic instability.
Ehlers-Danlos Syndrome, especially the hypermobile type (hEDS): The connective tissue laxity in EDS appears to make mast cell membranes more reactive. The “triad” of MCAS + POTS + hEDS is well-described in the literature and is something we screen for at Venturis Clinic, as one of the few clinics in Oklahoma with a focus on EDS.
Long COVID: A substantial subset of long COVID patients meet criteria for MCAS. The post-viral immune dysregulation appears to unmask or trigger mast cell activation in susceptible patients.
Chronic Lyme and other tick-borne illnesses: Persistent infections can drive mast cell activation; treating one without the other often plateaus progress.
Vagus nerve dysfunction: Mast cells are densely innervated by the vagus nerve, and parasympathetic tone modulates their reactivity. This is part of why “calming the nervous system” actually changes mast cell behavior, not just stress levels.
What Integrative MCAS Care Looks Like
There is no single treatment that resolves MCAS, and any clinic that promises one is overselling. Care is layered, individualized, and adjusted over months. A reasonable framework includes:
Foundation — Identifying and Reducing Triggers
A trigger inventory — foods, medications, environments, hormonal patterns — is the foundation. Low-histamine eating trials, fragrance avoidance, mold remediation if indicated, and infection screening are typical first steps. This phase is mostly clinical detective work, not a prescription pad.
Mast Cell Stabilization
Standard pharmacologic options include H1 antihistamines (such as cetirizine or fexofenadine), H2 blockers (such as famotidine), and stabilizers like cromolyn sodium or ketotifen. Natural mediator-modulating agents — quercetin, luteolin, vitamin C, and specific forms of bioavailable curcumin — are sometimes used adjunctively under physician guidance. None of these are cures; they are tools for reducing reactivity while underlying drivers are addressed.
Addressing Underlying Drivers
This is where integrative medicine adds the most. Common drivers worth investigating: chronic gut dysbiosis, mold or mycotoxin exposure, persistent viral or bacterial infections, heavy metal burden, and unresolved trauma affecting vagal tone. Each requires its own workup and is approached one variable at a time.
Supportive IV and Infusion Therapies
For patients who tolerate them, certain IV therapies are used as adjunctive support — not as MCAS treatments per se. Examples include high-dose vitamin C, glutathione, and Plaquex (phosphatidylcholine) for membrane support. Ozone-based therapies such as EBOO are sometimes considered in patients with significant inflammatory or post-viral overlap, always with careful candidacy screening. These are individual decisions made with a clinician who understands MCAS reactivity and can adjust dosing accordingly.
Nervous System Work
Because vagal tone meaningfully affects mast cell behavior, parasympathetic work — breathwork protocols, vagal exercises, paced exposure to triggers, and in some cases targeted somatic therapies — is part of a complete care plan, not an afterthought.
How to Find a Clinician Who Will Take MCAS Seriously
Most primary care physicians have limited training in MCAS. When you are evaluating a clinician, look for:
- Willingness to consider the full symptom pattern across organ systems rather than referring out for each symptom.
- Familiarity with the Valent / TMS diagnostic criteria, including timed mediator collection.
- Awareness of the MCAS-POTS-EDS overlap and willingness to coordinate care.
- A care model that combines trigger reduction, mast cell stabilization, and root-cause investigation — not just a prescription.
- Honesty about what can and cannot be promised. MCAS care is iterative.
If you are in Oklahoma City or Tulsa and looking for that kind of care, we welcome a conversation. You can learn more about our approach on our MCAS treatments page, or read about related conditions including our work with long COVID, vagus nerve dysfunction, and our integrative approach to autoimmune disorders.
Frequently Asked Questions
Is MCAS an allergy?
No. MCAS is mast cell over-activation, which is distinct from IgE-mediated allergy. Standard allergy testing typically comes back normal in MCAS patients, which is one reason it is missed.
Can MCAS develop in adulthood?
Yes. Many patients trace their symptoms to a triggering event — a viral infection (including COVID-19), a surgery, a pregnancy, a tick-borne illness, or a period of intense stress — even though some retrospectively recognize milder symptoms earlier in life.
Is MCAS treatable?
MCAS is manageable. Many patients achieve substantial symptom reduction with a layered approach over months. There is no single cure, and care is adjusted over time. Outcomes vary by individual.
What testing should I ask for?
Discuss with your clinician: timed serum tryptase (baseline and during a flare), 24-hour urine for N-methylhistamine, prostaglandin D2, and leukotriene E4, and ruling out systemic mastocytosis if indicated. The collection timing matters more than which lab runs the panel.
How long does it take to feel better?
Patients with MCAS typically describe a months-to-years arc, not days. Early phases focus on trigger reduction and stabilization; later phases address drivers. Patience and consistent re-assessment are part of the process.
Do I need to see a specialist if my primary care is helpful?
Not necessarily, but a clinician with specific MCAS familiarity will collect mediator labs correctly, recognize the overlap conditions, and avoid common pitfalls (such as prescribing medications with histamine-releasing properties). It often shortens the path significantly.
Considering integrative care for MCAS in Oklahoma City or Tulsa?
At Venturis Clinic we approach MCAS as part of a larger picture — looking at autonomic function, the MCAS-POTS-EDS overlap, post-viral drivers, and the underlying terrain that shapes mast cell reactivity. We do not promise cures, and we are honest about what care looks like over time.
This article is educational and is not medical advice. Always consult a qualified clinician for diagnosis and treatment decisions specific to your situation. Author: Dr. Alvin Philipose, DC.